Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of inhaled treprostinil in pulmonary hypertension associated with COPD
MOH_2021-02-16_009767Phase 3Completed
- Sponsor
- United Therapeutics Corporation
- Start
- Nov 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of treprostinil in Pulmonary hypertension associated with chronic obstructive pulmonary disease (COPD-PH), sponsored by United Therapeutics Corporation. Primary endpoint: Long-term safety and tolerability of inhaled treprostinil. Started Nov 2020; status: completed.
02
Drugs
treprostinil
03
Conditions
Pulmonary hypertension associated with chronic obstructive pulmonary disease (COPD-PH)
Beyond the preview
Go deeper on MOH_2021-02-16_009767.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-02-16_009767.